Sanofi Korea – Kay Bae, General Manager
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY). In Korea, Sanofi has four legal entities in the fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea), vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health (Merial Korea).
Contact details
137-804 Hyosung building 10F Banpo-daero 235, Seocho, Seoul, Korea
Tel +82 2 2136 9000
Fax +82 2 2136 9099
Email infor@sanofi.co.kr
Sanofi’s Korean affiliate is the fifth largest recipient of clinical trial investments after the United States, France, Germany and the United Kingdom. Kay Bae, general manager, discusses the benefits of…
Song In-Keum, chairman of the Korean Medical Devices Industry Association (KMDIA), discusses current opportunities offered by Korea’s growing medtech industry. What have been your priorities since you became the…
The Korean Institute of Toxicology (KIT) is a government-funded research institute that evaluates the safety of medicine, bio-related products and chemicals. PharmaBoardroom talks to Lee Sang-Joon, President of KIT about…
Korea possesses enormous potential to become an exporter of futuristic health systems in the near future, and has already started the process. Kim Han-Joong, chairman of the strategy committee at…
The Korea Drug Research Association (KDRA) was founded in 1986 to represent local pharmaceutical companies in their mission for global drug development. Kang-Choo Lee, president of KDRA, discusses the current…
The president of Astellas Korea offers his perspectives on Korea as a base for primary and clinical research, and the company’s recent partnerships in the country. You became president…
The head researcher at P&K Skin Research Center discusses the potential of South Korea as a clinical trial hub, and the company’s current expansion plans. What differentiates P&K Skin…
Don Hyun, president of MSD Korea, shares his vision to bring Korean pharmaceutical companies to the global stage and to bring a locally produced drug to blockbuster status in the…
The director of the Hanyang University Hospital for Rheumatic Diseases (HUHRD), discusses Korea’s leading role in developing biosimilars as well as the hospital’s efforts to curb chronic diseases. As…
The Korea National Enterprise for Clinical Trials (KoNECT) was established in 2007 by the Korean government to meet the increasing demand for local clinical trials and strengthen the country’s clinical research…
The director general of Korea’s Bureau of Health Industry explains what has led to Korea’s excellent healthcare system, and the competitiveness of the country’s pharmaceutical sector. Can you provide our…
Jung Kee-Taig, president of the Korea Health Industry Development Institute (KHIDI), outlines his “Health Economy 2030” for Korea, and highlights the institute’s domestic and international collaborations. KHIDI aims to…
Prior to founding Bioneer, Park Han-Oh spent a number of years working at KRIBB. Today he speaks about the company’s latest breakthrough technology in DNA synthesis and his outlook for…
See our Cookie Privacy Policy Here
